Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Carcinoma, Renal Cell 13Neoplasm Metastasis 12Prostatic Neoplasms 9Neoplasms 7Glioblastoma 7Kidney Neoplasms 6Brain Neoplasms 6Sarcoma 5Carcinoma, Hepatocellular 5Ovarian Neoplasms 4Lymphoma, Non-Hodgkin 4Glioma 4Endometrial Neoplasms 4Colorectal Neoplasms 4Central Nervous System Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Advanced Cancer 4Uterine Cervical Neoplasms 3Recurrence 3Pancreatic Neoplasms 3Oligodendroglioma 3Multiple Myeloma 3Lymphoma, Mantle-Cell 3Liver Neoplasms 3Astrocytoma 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2

Interventions

cobimetinib 2trametinib 1temsirolimus 1dabrafenib 1Vemurafenib 1Valproic Acid 1Specimen Handling 1Sirolimus 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Immunoglobulin G 1Disulfides 1Cetuximab 1Biopsy 1Bevacizumab 168Ga-pentixafor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Erdheim-Chester Disease × temsirolimus × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡